Group 1: Sales Revenue Breakdown - In 2024, the sales revenue by business segment is projected as follows: - Optical Display: 55,159 (up 114% from 2023) - New Energy: 47,108 (up 61% from 2023) - Microelectronics: 11,222 (up 24% from 2023) - Civil Adhesive Tape: 47,030 (up 16% from 2023) - PET Film: 14,080 (up 158% from 2023) - Other Functional Adhesive Products: 94,457 (up 9% from 2023) - Total Revenue: 269,055 (up 37% from 2023) [2][4] Group 2: Future Revenue Expectations - The company has set performance targets for sales revenue growth based on 2024 figures: - 2025: 40% increase (37.67 billion) - 2026: 75% increase (47.09 billion) - 2027: 120% increase (59.20 billion) [3] Group 3: Growth Drivers - Key factors for sustained revenue growth include: - Completion of large-scale expansion projects, leading to a revenue growth phase - Continuous development of new products and clients, enhancing capabilities to serve major manufacturers - Readiness to capitalize on opportunities arising from the trend of domestic substitution for "bottleneck" materials [4] Group 4: Business Segment Highlights - The Optical Display segment is the most promising, with significant R&D investment and high product value. The market is largely dominated by US and Japanese suppliers, but recent experience in foldable screens and VR glasses positions the company well for growth [5] Group 5: Revenue vs. Profit Analysis - In 2024, despite a 37% increase in sales revenue, profit margins are affected by rising costs: - Depreciation: 37,218 (up 49% from 2023) - Labor Costs: 37,516 (up 22% from 2023) - R&D Expenses: 12,610 (up 41% from 2023) - Financial Costs: 10,643 (up 47% from 2023) - Total Costs: 97,988 (up 36% from 2023) [6][7] Group 6: Cost Structure Insights - Major cost increases are attributed to: - Transition of construction projects to fixed assets, leading to higher depreciation - Significant investments in R&D, technology, and human resources - Shift from capitalized borrowing costs to expense recognition, increasing financial costs - Fixed costs will be diluted as sales scale increases, leading to anticipated economies of scale [8]

| | ☑特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 □路演活动 | | | ☑现场参观 □其他（线上交流会） | | 参与单位名 | 深交所投资者服务部、申万宏源证券组织的投资者"走进上市公司"一行个人 | | 称及人员 | 投资者 33 人 | | 时间 | 2025 年 5 月 27 日 14：30-16：00 | | 地点 | 广西贺州西麦生物食品有限公司 | | 形式 | 线下 | | 上市公司 接待人员 | 证券事务代表：何剑萍 | | | 公司工作人员带领投资者参观公司展厅、部分生产车间，讲解企业发展历程、 | | | 核心业务，主要产品。向投资者介绍公司近年来的整体发展情况和未来发展规 | | | 划，并就投资者关注的问题进行了交流。 | | | Q1：2025 年一季度公司营收和利润增长主要来自于哪些方面？ | | | A1：春节在一季度，是传统的销售旺季：1、电商一季度增速较高。一季度电 | | 投资者关系 | 商的增长主要来自于传统电商平台，传统电商平台盈利能力高于兴趣电商平 | | 活动主 ...

Group 1: Seasonal Business Characteristics - The company's revenue is relatively low in Q1 and higher in Q4 due to seasonal factors, as clients often choose to replace equipment during holiday or maintenance periods [2][3] - The installation and testing of equipment typically take 3 to 6 months, leading to a delay in revenue recognition until Q4 when clients issue acceptance documents [2] Group 2: Overseas Market Expansion - The company is actively expanding into overseas markets, with new projects launched in Mexico, Saudi Arabia, Vietnam, Czech Republic, and Taiwan in 2024 [3] Group 3: Fundraising and Financial Strategy - The purpose of the recent private placement is to support business expansion, enhance risk resistance, and stabilize control [4] - The funds raised will be used to supplement working capital, reduce debt ratios, and improve liquidity [4] Group 4: Technological Innovations - The company is investing in AI and smart technologies to enhance product efficiency and maintenance [5][6] - Focus areas for R&D include high-efficiency centrifugal pumps and motors, as well as energy-saving combustion technologies [6] Group 5: Client Acquisition in Steel Industry - In 2024, the company signed contracts with over 27 steel enterprises, including 11 new clients [10] - The company has engaged with over 60 steel companies for project discussions, significantly expanding collaboration intentions [10] - Energy-saving solutions have achieved over 35% energy reduction in specific projects, enhancing client investment recovery [10] Group 6: Accounts Receivable Management - The company employs a policy based on expected credit losses to assess and prepare for bad debts, ensuring the adequacy and reasonableness of provisions [7][8]

证券代码：000088 证券简称：盐田港 布局，进一步巩固了盐田港区在华南地区港口行业的核心地位。谢 谢！ 深圳市盐田港股份有限公司 投资者关系活动记录表 编号：2025-2 | 投资者关系活动类别 | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | | 线上参与公司2024年度网上业绩说明会的投资者 | | 参与单位名称及人员姓名 | | | 时间 | 2025年05月28日 15:00-16:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | | 董事长 李雨田 董事 乔宏伟 | | | 总经理 李安民 | | 上市公司接待人员姓名 | 监事会主席 凌平 | | | 独立董事 应华东 | | | 财务总监 陈旭阳 | | | 董事会秘书 罗静涛 | | | 独立财务顾问主办人 韩冬 | | | 1.公司2024年分红率为43.3%，未来三年分红规划提及"保持 | | | 连续性"。在资本开支高 ...

证券代码：300923 证券简称：研奥股份 研奥电气股份有限公司 投资者关系活动记录表 | 投资者关系活动 | □特定对象调研□分析师会议 | | | | | --- | --- | --- | --- | --- | | 类别 | □媒体采访√业绩说明会 | | | | | | □新闻发布会□路演活动 | | | | | | □现场参观 | | | | | | □其他（请文字说明其他活动内容） | | | | | 参与单位名称及 | 投资者网上提问 | | | | | 人员姓名 | | | | | | 时间 | 2025 年 27 (周二) 下午 15:00~16:30 | 5 | 月 | 日 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | | | 采用网络远程的方式召开业绩说明会 | | | | | 上市公司接待人 | 1、董事、总经理闫兆金 | | | | | 员姓名 | 2、董事、副总经理、财务总监、董事会秘书石娜 | | | | | | 1、截至 2024 年末和 2025 年第一季度末，公司在手订单的金 | | | | | | 额和数 ...

Group 1: Company Strategy and Goals - During the "14th Five-Year Plan" period, the company focused on creating a specialized first-class securities firm in the power and energy sectors, guided by Xi Jinping's thoughts and the spirit of the 20th National Congress [1] - The company aims to enhance its core competitiveness and establish a new ecosystem for industrial finance, emphasizing the importance of serving the real economy [2] Group 2: Industry Trends and Mergers - Since the 2023 Central Financial Work Conference, regulatory support for mergers and acquisitions (M&A) has increased, making it a crucial strategy for securities firms to enhance competitiveness [3] - The trend of M&A is expected to reshape the industry landscape, with leading firms innovating through group operations and M&A to strengthen their positions [3] Group 3: Investment and Financial Performance - In Q1 2025, the company reported a significant increase in investment income and fair value changes, attributed to optimized asset allocation and market timing strategies [5] - The company successfully captured structural opportunities in the equity market while managing risks in the bond market, leading to substantial year-on-year investment returns [5] Group 4: Future Development and Internationalization - The company plans to develop two fund companies to align with national strategic areas such as technology innovation and green development, aiming to enhance its market position and product offerings [4] - The focus will be on creating comprehensive solutions that meet the long-term capital market needs, thereby supporting high-quality market development [4]

Production Capacity and Inventory - The company's current production capacity is 15,000 tons, with an additional 7,800 tons expected after the completion of the Phase II project [2] - As of the end of 2024, the company's base liquor inventory stands at 46,769 tons [2] Strategic Focus and Market Positioning - The company is implementing a differentiation and focus strategy to navigate the dual adjustment period in the industry and internally [3] - The company aims to enhance its competitive edge through unique products, regional characteristics, and cultural aspects [3] - The company is focusing on the Hunan market and model markets, emphasizing core products [3] Financial Performance and Sales Strategy - In 2024, the company achieved revenue exceeding 1 billion yuan, with efforts to enhance sales quality and brand strength [3] - The company has seen a significant increase in terminal sales and consumer engagement, with distribution and sales rates exceeding 100% in 2024 [4] - The company plans to maintain a focus on high-quality sales and improve brand, product, channel, and system capabilities [4] Product Line and Market Adaptation - The company has reduced its SKU by 50% to eliminate low-efficiency products and is developing new products based on market demand [5] - The company is actively working to stabilize product prices through dynamic inventory management and targeted promotions [5] Distributor Management and Market Expansion - In 2024, the company reduced its number of distributors by over 400, focusing on improving distributor quality [5] - The company is expanding its presence in the small liquor market to cater to diverse consumer needs [6] Industry Challenges and Future Outlook - The company acknowledges the challenges posed by the current industry adjustment, which has intensified competition [6] - The company is committed to leveraging its unique advantages to establish itself as a differentiated premium liquor brand [6]

Group 1: Company Performance and Strategy - In Q1 2025, the company installed over 400 high-speed instruments in the domestic market, improving reagent sales ratio through optimized sales structure [2] - The company adjusted its international sales strategy, focusing on Southeast Asia and Belt and Road countries, with minimal impact from uncontrollable factors [2] - The management aims to enhance reagent sales, reduce costs, and improve operational efficiency in response to performance challenges [2] Group 2: Profit Distribution and Shareholder Returns - The profit distribution plan for 2024 involves a cash dividend of RMB 2.60 per 10 shares, based on a total share capital of 272,700,161 shares, implemented on May 20, 2025 [3] - The company emphasizes long-term development while balancing short-term profit distribution to enhance investor returns [3] Group 3: Cost Reduction and Efficiency Improvement - The company is implementing measures to reduce costs and improve efficiency, including strengthening internal management and optimizing financial controls [4] - Ongoing efforts are focused on enhancing risk management capabilities to ensure sustainable profitability [4] Group 4: Research and Development Investments - The company is committed to R&D innovation, launching competitive products like the CS-690 automatic urine biochemical analyzer and CM-640 automatic chemiluminescence immunoassay analyzer [5][6] - R&D efforts are aligned with market trends, particularly in smart medical technology, enhancing the company's innovation capabilities [5][6] Group 5: Future Performance Improvement Measures - The company will focus on increasing reagent sales, improving accounts receivable, cash flow, and inventory management, while implementing a four-dimensional management approach [7] - The management is dedicated to ensuring stable and healthy company development [7] Group 6: Market Trends and Challenges - The in vitro diagnostic industry is driven by aging populations, domestic substitution, and new medical infrastructure, presenting opportunities for market share growth [9] - The company has established competitive advantages through over 30 years of independent R&D and has expanded its products to over 120 countries [9] Group 7: Market Value Management - The company has established a market value management system linked to executive performance evaluations, recognizing the importance of market performance for shareholder value [8] - The company plans to regularly review and adjust its market value management strategies in response to market conditions [8]

答：2025 年，在风险管理方面，公司将持续优化全面风险管 理体系，运用数字化工具强化市场、供应链及合规风险的实时 监测与预警；在内部控制方面，公司将推进关键业务流程自动 化，确保符合监管要求；在公司治理方面，公司也将积极开展 治理层培训，进一步提升治理能力，同时将加强中小股东沟通， 保障中小股东权益。 3、公司在研发上的投入如何？ 证券代码：002912 证券简称：中新赛克 深圳市中新赛克科技股份有限公司投资者关系活动记录表 编号：2025-005 投资者关系活动 类别 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 活动参与人员 调研单位及人员： 华创证券 吴鸣远、祝小茜 公司接待人员： 董事会秘书兼财务总监李斌 时间 2025 年 5 月 27 日下午 15:00-15:30 地点 南京中新赛克科技有限责任公司会议室 形式 现场调研 交流内容及具体 问答记录 互动问答： 1、公司围绕 ToG+ToB 双轮驱动战略目标，具体如何布局？ 答：公司坚持"ToG+ToB"双轮驱动，国内国际均衡发展的整 体战略。公司将加大渠道生态建设力度，确保公司整体战略得 ...

Group 1: Company Performance and Financials - In 2024, the company achieved a revenue of 775 million CNY, a year-on-year increase of 12.04% [4] - In Q1 2025, the company reported a revenue of 239 million CNY, a year-on-year increase of 4.62%, with a slowdown attributed to reduced market demand for key products [4] - The five key traditional Chinese medicine products saw a slight revenue increase of 0.93% in Q1 2025, with notable growth in specific products like Liuwei Anshen Capsules (32.10% increase) and Tongxie Ning Granules (80.24% increase) [4] Group 2: Research and Development - The company has integrated its R&D pipeline with Chengdu Aorui Pharmaceutical, resulting in 7 independent Class 1 innovative drug projects targeting various cancers and autoimmune diseases [3] - The lead project, ORIC-1940, is in clinical phase Ia/Ib and is expected to be the first Class 1 innovative drug for secondary hemophagocytic lymphohistiocytosis in China [3] - The company has established multiple R&D platforms and has applied for 35 patents, including 17 PCT patents [3] Group 3: Product Development and Market Strategy - The company has 4 self-researched special medical foods projects, with the TY005 project receiving regulatory approval, marking a breakthrough in the special medical food sector [4] - The five key traditional Chinese medicine products are in a growth phase, with plans for further market expansion and academic promotion to enhance market access [5][6] - The company aims to launch at least 3 new drug varieties annually over the next five years, alongside special medical foods and health consumer products [12] Group 4: International Expansion - The company successfully passed the FDA's cGMP inspection for its fifth production base, facilitating international quality standards [7] - Key traditional Chinese medicine products have received registration approvals for sale in Singapore, marking a significant milestone for international market entry [7] Group 5: Corporate Governance and Investor Relations - The company emphasizes transparent communication with investors, regularly hosting performance briefings and investor engagement activities [8] - Independent directors play a crucial role in overseeing the accuracy and completeness of financial reports, ensuring compliance with regulatory standards [9] Group 6: Future Strategic Focus - The company will focus on high-quality development, leveraging talent and innovation to enhance its competitive edge in the pharmaceutical industry [10] - Plans include expanding into oncology and autoimmune disease research, while also enhancing the efficiency of generic drug development [11]